{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:55Z","timestamp":1761630595369},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.numecd.2011.07.002","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T00:16:08Z","timestamp":1317600968000},"page":"330-336","source":"Crossref","is-referenced-by-count":13,"title":["Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile"],"prefix":"10.1016","volume":"23","author":[{"given":"T.D.","family":"Filippatos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Tsimihodimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.S.","family":"Derdemezis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.F.","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Saougos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2011.07.002_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2011.07.002_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14712598.7.1.53","article-title":"Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles","volume":"7","author":"Gazi","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.numecd.2011.07.002_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bbalip.2009.02.015","article-title":"The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma","volume":"1791","author":"Tellis","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.numecd.2011.07.002_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.numecd.2011.07.002_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157016110790226679","article-title":"Visfatin\/PBEF and atherosclerosis-related diseases","volume":"8","author":"Filippatos","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.numecd.2011.07.002_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2362.2007.01904.x","article-title":"Increased plasma visfatin levels in subjects with the metabolic syndrome","volume":"38","author":"Filippatos","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2011.07.002_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF03346300","article-title":"Increased plasma levels of visfatin\/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome","volume":"30","author":"Filippatos","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.numecd.2011.07.002_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1758-5996-2-21","article-title":"Visfatin, glucose metabolism and vascular disease: a review of evidence","volume":"2","author":"Saddi-Rosa","year":"2010","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.numecd.2011.07.002_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.286.2.180","article-title":"Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation","volume":"286","author":"D\u2019Agostino","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2011.07.002_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2265.2008.03453.x","article-title":"Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans","volume":"71","author":"Liu","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2011.07.002_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2010.09.012","article-title":"Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study","volume":"412","author":"Kadoglou","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.numecd.2011.07.002_bib12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1517\/14656566.9.10.1629","article-title":"Effects of sibutramine plus verapamil sustained release\/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients","volume":"9","author":"Nakou","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.numecd.2011.07.002_bib13","first-page":"9","article-title":"Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome","volume":"2","author":"Filippatos","year":"2007","journal-title":"J Med Sci Res"},{"key":"10.1016\/j.numecd.2011.07.002_bib14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1517\/14656566.9.11.1829","article-title":"Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study","volume":"9","author":"Derdemezis","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.numecd.2011.07.002_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejphar.2007.09.019","article-title":"Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia","volume":"578","author":"Kostapanos","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.numecd.2011.07.002_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/ajcn\/85.2.399","article-title":"Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men","volume":"85","author":"Sun","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.numecd.2011.07.002_bib17","first-page":"273","article-title":"Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients","volume":"34","author":"Mirzaei","year":"2009","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.numecd.2011.07.002_bib18","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2527\/jas.2010-2799","article-title":"Visfatin regulates genes related to lipid metabolism in porcine adipocytes","volume":"88","author":"Yang","year":"2010","journal-title":"J Anim Sci"},{"key":"10.1016\/j.numecd.2011.07.002_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/HCO.0b013e3283043806","article-title":"Multiple actions of high-density lipoprotein","volume":"23","author":"Florentin","year":"2008","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.numecd.2011.07.002_bib20","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.metabol.2008.06.011","article-title":"The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects","volume":"57","author":"Johansson","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2011.07.002_bib21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1515\/CCLM.2006.207","article-title":"A long and winding road: defining the biological role and clinical importance of paraoxonases","volume":"44","author":"James","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.numecd.2011.07.002_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1567-5688(02)00046-6","article-title":"Paraoxonase and coronary heart disease","volume":"3","author":"Mackness","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.numecd.2011.07.002_bib23","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1373\/clinchem.2005.058404","article-title":"Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma","volume":"51","author":"Gazi","year":"2005","journal-title":"Clin Chem"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475311001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475311001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T22:36:58Z","timestamp":1560724618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475311001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0939475311001670"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2011.07.002","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}